Core Insights - Medidata has introduced a transformative vision for the life sciences industry, unveiling AI-based virtual companions and a new AI ecosystem that aims to enhance clinical trial processes and patient therapy delivery [1][8] Group 1: AI Companion and Platform - The flagship AI companion, Dot, integrates Medidata Study, Data, and Patient Experiences, streamlining clinical workflows and enhancing trial optimization through a vast data library from 38,000 research studies involving over 12 million patients [2][5] - Dot automates complex workflows, significantly reducing study build timelines from weeks to hours, allowing teams to transition from design to execution with improved precision [5][6] Group 2: Real-Time Insights and Simulations - The platform enables continuous updates of plans and forecasts in real time as new data flows in, providing unprecedented insight, speed, and control in clinical trial planning [6] - Virtual workspaces allow teams to design, test, and simulate trial performance and financial outcomes before patient enrollment, enhancing overall trial strategy [5][6] Group 3: Industry Impact and Leadership - Dassault Systèmes' extensive reach in the life sciences value chain is highlighted, with a focus on overcoming bottlenecks to expedite the delivery of life-saving therapies [7][8] - Medidata's 25 years of industry knowledge has been transformed into an intelligence layer that bridges gaps and fosters connectivity across the life sciences sector [8] Group 4: Event and Collaboration - The NEXT New York 2026 event gathered over 1,000 global life sciences leaders to discuss the impact of AI and orchestrated intelligence on clinical trials, featuring nearly 50 keynotes and interactive sessions [9] - Collaboration with industry leaders such as AbbVie, BMS, and Pfizer emphasizes the collective effort to innovate and improve clinical development processes [9]